BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2026)

BioNexus Gene Lab has disclosed Cost of Revenue across 9 years of filings, most recently posting $52733.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $52733.0, down 97.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 514.23% YoY), and the FY2025 annual result was $6.3 million, up 212.2% from the prior year.
• Cost of Revenue came in at $52733.0 for Q1 2026 at BioNexus Gene Lab, down from $487743.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q1 2022 to a low of -$4.0 million in Q4 2024.
• The 5-year median for Cost of Revenue is $2.0 million (2023), against an average of $1.3 million.
• Across the five-year window, Cost of Revenue sank 298.15% in 2024 and jumped 345.75% in 2025, its largest moves.
• BioNexus Gene Lab's Cost of Revenue stood at $2.5 million in 2022, then slipped by 19.75% to $2.0 million in 2023, then tumbled by 298.15% to -$4.0 million in 2024, then jumped by 112.27% to $487743.0 in 2025, then tumbled by 89.19% to $52733.0 in 2026.
• The last three Cost of Revenue figures came in at $52733.0 (Q1 2026), $487743.0 (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.